<DOC>
	<DOCNO>NCT02934412</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single dose escalating , study 5 sequential cohort investigate effect single s.c. injection SHR-1314 5 dose level ( 20mg , 40mg , 80mg , 160mg , 240mg ) healthy subject . Each cohort consist 6 subject receive active drug 2 subject receive placebo , total approximately 40 subject dose one study site .</brief_summary>
	<brief_title>A Study SHR-1314 Healthy Subjects</brief_title>
	<detailed_description>This study consist 27-day screening period ( Days -28 -2 ) , clinic check-in ( Day -1 ) , treatment day ( Day 1 ) , 10-week treatment period study completion evaluation ( Day 71 ) show figure . A review blind interim PK data conduct Safety Review Committee ( SRC ) confirm study sample schedule capture full PK profile SHR-1314 . This interim analysis conduct Cohort 1 may conduct subsequent cohort serum SHR-1314 concentration Cohort 1 subsequent cohort limit quantification assay prevent evaluation PK profile . The expected duration participation subject 99 day . Subjects withdraw reason safety may replace discretion sponsor .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Provide write informed consent study assessment perform . 2 . Male female age 18 55 year ( inclusive ) screening , 3 . Good general health define clinically relevant abnormality identify detailed medical history , full physical examination include measurement vital sign , 12lead ECG , clinical laboratory test . ( Evaluations must consider `` clinically significant ( NCS ) '' outside reference range ) . 4 . Body Mass Index ( BMI ) 18 30 kg/m2 ( inclusive ) , total body weight â‰¥50 kg screening . 5 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure specify protocol . 1 . Subjects investigational site staff member subject Sponsor employee directly involve conduct study . 2 . Use investigational drug within 5 halflives screen , within 30 day screen ( small molecule ) , expect pharmacodynamic effect return baseline ( biologics ) , whichever longer . 3 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive human chorionic gonadotropin laboratory test screen Day 1 . 4 . Females childbearing potential ( defined female physiologically capable become pregnant ) males unwilling unable use effective contraception study 2 month drug administration ( approximately 5 halflives ) . Effective contraception define use two follow method contraception : Barrier method : Condom Occlusive cap ( diaphragm cervical/vault cap ) . Female sterilization : surgical bilateral oophorectomy ( without hysterectomy ) tubal ligation least six week take study treatment . In case oophorectomy alone , reproductive status woman confirm follow hormone level assessment . Male sterilization Use establish oral , injected implant hormonal method contraception , Use intrauterine device intrauterine system . 5 . Blood donation approximately 500 mL within 56 day prior dose Day 1 duration study . 6 . A positive urine drug screen screen Day 1 . 7 . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 100 mL wine 360 mL beer 45 mL hard liquor ) within 6 month screen . 8 . Use tobacco nicotine containing product ( include ecigarettes ) time within six month screen duration study . 9 . History hypersensitivity study biologics , drug drug similar chemical class . 10 . History malignancy organ system , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis . 11 . History complication tuberculosis . 12 . Has clinically significant abnormality screen chest xray , opinion investigator , could affect subject 's safety ability participate study ; include , limited , evidence previous exposure tuberculosis . 13 . History immunodeficiency disease , include positive human immunodeficiency virus ( HIV ) test result screen . 14 . Positive hepatitis B hepatitis C test result Screening 15 . Recent ( within last 3 year ) and/or recurrent history acute chronic bronchospastic pulmonary disease ( include asthma chronic obstructive pulmonary disease , treat treat ) . 16 . Use live vaccine ( attenuate ) within 3 month study Day 1 time study . 17 . Evidence latent tuberculosis QuantiFERON screening . 18 . Use follow , unless agree nonclinically relevant Investigator Sponsor : 1 . Prescription medication within four week prior dose Day 1 2 . Overthecounter medication ( exclude paracetamol ) within seven day prior treatment day . Paracetamol use must limit 2 g per day three day usage four week prior dose Day 1 3 . Vitamin therapy dietary supplement within seven day prior dose Day 1 duration study 4 . Herbal supplement within 28 day prior dose Day 1 duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>